المؤلفون: Peeters S. A., Engelen L., Buijs J., Chaturvedi N., Fuller J. H., Schalkwijk C. G., Stehouwer C. D., Karamanos B., Kofinis A., Petrou K., Giorgino F., Picca G., Angarano A., de Pergola. G., Laviola L., Giorgino R., Ionescu-Tirgoviste C., Coszma A., Guja C., Songini M., Casu A., Pedron M., Pintus S., Fossarello M., Ferriss J. B., Grealy G., O'Keefe D., Toeller M., Arden C., Rottiers R., Tuyttens C., Priem H., Ebeling P., Kylliainen M., Koivisto V. A., Idzior-Walus B., Sieradzki J., Cyganek K., Solnica B., Lemkes H. H. P. J., Lemkes-Stuffken J. C., Nunes-Correa J., Rogado M. C., Gardete-Correia L., Cardoso M. C., Silva A., Boavida J., Machado Sa Marques M., Michel G., Wirion R., Cardillo S., Pozza G., Mangili R., Asnaghi V., Standl E., Schaffler B., Brand H., Harms A., Ben Soussan M., Verier-Mine O., Fallas P., Fallas M. C., Holloway J., Asbury L., Betteridge D. J., Cathelineau G., Bouallouche A., Villatte Cathelineau B., Santeusanio F., Rosi G., D'Alessandro V., Cagini C., Bottini P., Reboldi G. P., Navalesi R., Penno G., Bandinelli S., Miccoli R., Nannipieri M., Ghirlanda G., Saponara C., Cotroneo P., Manto A., Minnella A., Ward J. D., Tesfaye S., Eaton S., Mody C., Borra M., Cavallo Perin P., Giunti S., Grassi G., Pagano G. F., Porta M., Sivieri R., Vitelli F., Veglio M., Papazoglou N., Manes G., Muggeo M., Iagulli M., Cacciatori V., Cattedra di Malattie del Metabolismo V., Irsigler K., Abrahamian H., Walford S., Sinclair J., Hughes S., McLelland V., Ward J., Roglic G., Metelko Z., Pepeonik Z. R.

المساهمون: Peeters, S. A., Engelen, L., Buijs, J., Chaturvedi, N., Fuller, J. H., Schalkwijk, C. G., Stehouwer, C. D., Karamanos, B., Kofinis, A., Petrou, K., Giorgino, F., Picca, G., Angarano, A., Pergola. G., De, Laviola, L., Giorgino, R., Ionescu-Tirgoviste, C., Coszma, A., Guja, C., Songini, M., Casu, A., Pedron, M., Pintus, S., Fossarello, M., Ferriss, J. B., Grealy, G., O'Keefe, D., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Koivisto, V. A., Idzior-Walus, B., Sieradzki, J., Cyganek, K., Solnica, B., Lemkes, H. H. P. J., Lemkes-Stuffken, J. C., Nunes-Correa, J., Rogado, M. C., Gardete-Correia, L., Cardoso, M. C., Silva, A., Boavida, J., Machado Sa Marques, M., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, M., Verier-Mine, O., Fallas, P., Fallas, M. C., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D'Alessandro, V., Cagini, C., Bottini, P., Reboldi, G. P., Navalesi, R., Penno, G., Bandinelli, S., Miccoli, R., Nannipieri, M., Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, A., Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Borra, M., Cavallo Perin, P., Giunti, S., Grassi, G., Pagano, G. F., Porta, M., Sivieri, R., Vitelli, F., Veglio, M., Papazoglou, N., Manes, G.

مصطلحات موضوعية: Albuminuria, Cardiovascular disease, Matrix metalloproteinase, Retinopathy, Tissue inhibitor of metalloproteinase, Type 1 diabete, Adult, Biomarker, Cohort Studie, Cross-Sectional Studie, Diabetes Complication, Diabetes Mellitus, Type 1, Europe, Female, Human, Male, Matrix Metalloproteinase 10, Matrix Metalloproteinase 2, Matrix Metalloproteinase 3, Middle Aged, Prospective Studie, Tissue Inhibitor of Metalloproteinase-1, Vascular Diseases

الوصف: Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1 diabetes. We investigated associations between plasma MMP-1, -2, -3, -9, -10 and TIMP-1, and cardiovascular disease (CVD) or microvascular complications in type 1 diabetic patients. We also evaluated to which extent these associations could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED). Methods: 493 type 1 diabetes patients (39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective Complications Study were included. Linear regression analysis was applied to investigate differences in plasma levels of MMP-1, -2, -3, -9, -10, and TIMP-1 between patients with and without CVD, albuminuria or retinopathy. All analyses were adjusted for age, sex, duration of diabetes, Hba1c and additionally for other cardiovascular risk factors including LGI and ED. Results: Patients with CVD (n = 118) showed significantly higher levels of TIMP-1 [β = 0.32 SD (95%CI: 0.12; 0.52)], but not of MMPs, than patients without CVD (n = 375). Higher plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1 were associated with higher levels of albuminuria (p-trends were 0.028, 0.004, 0.005 and 0.001, respectively). Severity of retinopathy was significantly associated with higher levels of MMP-2 (p-trend = 0.017). These associations remained significant after further adjustment for markers of LGI and ED. Conclusions: These data support the hypothesis that impaired regulation of matrix remodeling by actions of MMP-2, -3 and-10 and TIMP-1 contributes to the pathogenesis of vascular complications in type 1 diabetes.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/25848912; info:eu-repo/semantics/altIdentifier/wos/WOS:000350726000001; volume:14; issue:1; firstpage:31; journal:CARDIOVASCULAR DIABETOLOGY; http://hdl.handle.net/11586/353539Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84925234995

الإتاحة: https://doi.org/10.1186/s12933-015-0195-2Test
http://hdl.handle.net/11586/353539Test

المؤلفون: van Bussel BC, Soedamah Muthu SS, Henry RM, Schalkwijk CG, Ferreira I, Karamanos B, Kofinis A, Petrou K, Giorgino F, Picca G, Angarano A, De Pergola G, Laviola L, Giorgino R, Ionescu Tirgoviste C, Coszma A, Guja C, Songini M, Casu A, Pedron M, Pintus S, FOSSARELLO, MAURIZIO, Ferriss J, Grealy G, O'Keefe D, Toeller M, Arden C, Rottiers R, Tuyttens C, Priem H, Ebeling P, Kylliäinen M, Koivisto V, Idzior Walus B, Sieradzki J, Cyganek K, Solnica B, Lemkes H, Lemkes Stuffken J, Nunes Correa J, Rogado M, Gardete Correia L, Cardoso M, Silva A, Boavida J, Machado Sa Marques M, Michel G, Wirion R, Cardillo S, Pozza G, Mangili R, Asnaghi V, Standl E, Schaffler B, Brand H, Harms A, Ben Soussan D, Verier Mine O, Fallas P, Fallas M, Fuller J, Holloway J, Asbury L, Betteridge D, Cathelineau G, Bouallouche A, Villatte Cathelineau B, Santeusanio F, Rosi G, D'Alessandro V, Cagini C, Bottini P, Reboldi G, Navalesi R, Penno G, Bandinelli S, Miccoli R, Nannipieri M, Ghirlanda G, Saponara C, Cotroneo P, Manto A, Minnella A, Ward J, Tesfaye S, Eaton S, Mody C, Borra M, Cavallo Perin P, Giunti S, Grassi G, Pagano G, Porta M, Sivieri R, Vitelli F, Veglio M, Papazoglou N, Manes G, Muggeo M, Iagulli M, Cacciatori V, Irsigler K, Abrahamian H, Walford S, Sinclair J, Hughes S, McLelland V, Roglic G, Metelko Z, Pepeonik Z, Sjolie A., Chaturvedi N, Ferriss B, Webb D, Viberti G., Swaminathan R, Lumb P, Collins A, Sankaralingham S, Crook MA, Aldington S, Mortemore T, Lipinski H, Scherbaum WA, Gries FA

المساهمون: van Bussel, Bc, Soedamah Muthu, S, Henry, Rm, Schalkwijk, Cg, Ferreira, I, Karamanos, B, Kofinis, A, Petrou, K, Giorgino, F, Picca, G, Angarano, A, De Pergola, G, Laviola, L, Giorgino, R, Ionescu Tirgoviste, C, Coszma, A, Guja, C, Songini, M, Casu, A, Pedron, M, Pintus, S, Fossarello, Maurizio, Ferriss, J, Grealy, G, O'Keefe, D, Toeller, M, Arden, C, Rottiers, R, Tuyttens, C, Priem, H, Ebeling, P, Kylliäinen, M, Koivisto, V, Idzior Walus, B, Sieradzki, J, Cyganek, K, Solnica, B, Lemkes, H, Lemkes Stuffken, J, Nunes Correa, J, Rogado, M, Gardete Correia, L, Cardoso, M, Silva, A, Boavida, J, Machado Sa Marques, M, Michel, G, Wirion, R, Cardillo, S, Pozza, G, Mangili, R, Asnaghi, V, Standl, E, Schaffler, B, Brand, H, Harms, A, Ben Soussan, D, Verier Mine, O, Fallas, P, Fallas, M, Fuller, J, Holloway, J, Asbury, L, Betteridge, D, Cathelineau, G, Bouallouche, A, Villatte Cathelineau, B, Santeusanio, F, Rosi, G, D'Alessandro, V, Cagini, C, Bottini, P, Reboldi, G, Navalesi, R, Penno, G, Bandinelli, S, Miccoli, R, Nannipieri, M, Ghirlanda, G, Saponara, C, Cotroneo, P, Manto, A, Minnella, A, Ward, J, Tesfaye, S, Eaton, S, Mody, C, Borra, M, Cavallo Perin, P, Giunti, S, Grassi, G, Pagano, G, Porta, M, Sivieri, R, Vitelli, F, Veglio, M, Papazoglou, N, Manes, G, Muggeo, M, Iagulli, M

مصطلحات موضوعية: Diet, Endothelial dysfunction, Epidemiologu

الوصف: BACKGROUND AND AIMS: A healthy diet has been inversely associated with endothelial dysfunction (ED) and low-grade inflammation (LGI). We investigated the association between nutrient consumption and biomarkers of ED and LGI in type 1 diabetes. METHODS AND RESULTS: We investigated 491 individuals. Nutrient consumption and lifestyle risk factors were measured in 1989 and 1997. Biomarkers of ED (von Willebrand factor, soluble vascular cell adhesion molecule-1 and soluble endothelial selectin) and LGI (C-reactive protein, interleukin 6 and tumour necrosis factor α) were measured in 1997 and averaged into Z-scores. The nutrient residual method was used to adjust individual nutrient intake for energy intake. Data were analysed with generalised estimation equations. We report increments/decrements in nutrient consumption, averaged over time, per +1 standard deviation (SD) of 1997 ED or LGI Z-scores, after adjustment for sex, age, duration of diabetes, investigation centre, body mass index, energy intake, smoking behaviour, alcohol consumption, and each of the other nutrients. One SD elevation in ED Z-score was associated with a diet lower in fibre [β(95%CI);-0.09(-0.18;-0.004)], polyunsaturated fat [-0.18(-0.31;-0.05)] and vegetable protein [-0.10(-0.20;-0.001)]. For the LGI Z-score results showed associations with fibre [-0.09(-0.17;-0.01)], polyunsaturated fat [-0.14(-0.24;-0.03)] and cholesterol [0.10(0.01; 0.18)]. CONCLUSION: In type 1 diabetes, consumption of less fibre, polyunsaturated fat and vegetable protein, and more cholesterol over the study period was associated with more ED and LGI. Following dietary guidelines in type 1 diabetes may reduce cardiovascular disease risk by favourably affecting ED and LGI.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/22795869; info:eu-repo/semantics/altIdentifier/wos/WOS:000321551300012; volume:23; issue:8; firstpage:758; lastpage:764; numberofpages:7; journal:NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES; http://hdl.handle.net/11584/58062Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84880046493

الإتاحة: https://doi.org/10.1016/j.numecd.2012.04.005Test
http://hdl.handle.net/11584/58062Test

المؤلفون: Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, Stehouwer CD, Karamanos B, Kofinis A, Petrou K, Giorgino F, Picca G, Angarano A, De Pergola G, Laviola L, Giorgino R, Ionescu Tirgoviste C, Coszma A, Guja C, Songini M, Casu A, Pedron M, Pintus S, FOSSARELLO, MAURIZIO, Ferriss JB, Grealy G, Keefe DO, Toeller M, Arden C, Rottiers R, Tuyttens C, Priem H, Ebeling P, Kylliäinen M, Koivisto VA, Idzior Walus B, Sieradzki J, Cyganek K, Solnica B, Lemkes HH, Lemkes Stuffken JC, Nunes Correa J, Rogado MC, Gardete Correia L, Cardoso MC, Silva A, Boavida J, Machado Sa Marques M, Michel G, Wirion R, Cardillo S, Pozza G, Mangili R, Asnaghi V, Standl E, Schaffler B, Brand H, Harms A, Ben Soussan D, Verier Mine O, Fallas P, Fallas MC, Holloway J, Asbury L, Betteridge DJ, Cathelineau G, Bouallouche A, Villatte Cathelineau B, Santeusanio F, Rosi G, D'Alessandro V, Cagini C, Bottini P, Reboldi GP, Navalesi R, Penno G, Bandinelli S, Miccoli R, Nannipieri M, Ghirlanda G, Saponara C, Cotroneo P, Manto A, Minnella A, Ward JD, Tesfaye S, Eaton S, Mody C, Borra M, Cavallo Perin P, Giunti S, Grassi G, Pagano GF, Porta M, Sivieri R, Vitelli F, Veglio M, Papazoglou N, Manes G, Muggeo M, Iagulli M, Irsigler K, Abrahamian H, Walford S, Sinclair J, Hughes S, McLelland V, Ward J, Roglic G, Metelko Z, Pepeonik ZR, Sjolie AK, Ferriss B, Webb D, Viberti GC, Swaminathan R, Lumb P, Collins A, Sankaralingham S, Aldington S, Mortemore T, Lipinski H.

المساهمون: Nin, Jw, Ferreira, I, Schalkwijk, Cg, Prins, Mh, Chaturvedi, N, Fuller, Jh, Stehouwer, Cd, Karamanos, B, Kofinis, A, Petrou, K, Giorgino, F, Picca, G, Angarano, A, De Pergola, G, Laviola, L, Giorgino, R, Ionescu Tirgoviste, C, Coszma, A, Guja, C, Songini, M, Casu, A, Pedron, M, Pintus, S, Fossarello, Maurizio, Ferriss, Jb, Grealy, G, Keefe, Do, Toeller, M, Arden, C, Rottiers, R, Tuyttens, C, Priem, H, Ebeling, P, Kylliäinen, M, Koivisto, Va, Idzior Walus, B, Sieradzki, J, Cyganek, K, Solnica, B, Lemkes, Hh, Lemkes Stuffken, Jc, Nunes Correa, J, Rogado, Mc, Gardete Correia, L, Cardoso, Mc, Silva, A, Boavida, J, Machado Sa Marques, M, Michel, G, Wirion, R, Cardillo, S, Pozza, G, Mangili, R, Asnaghi, V, Standl, E, Schaffler, B, Brand, H, Harms, A, Ben Soussan, D, Verier Mine, O, Fallas, P, Fallas, Mc, Holloway, J, Asbury, L, Betteridge, Dj, Cathelineau, G, Bouallouche, A, Villatte Cathelineau, B, Santeusanio, F, Rosi, G, D'Alessandro, V, Cagini, C, Bottini, P, Reboldi, Gp, Navalesi, R, Penno, G, Bandinelli, S, Miccoli, R, Nannipieri, M, Ghirlanda, G, Saponara, C, Cotroneo, P, Manto, A, Minnella, A, Ward, Jd, Tesfaye, S, Eaton, S, Mody, C, Borra, M, Cavallo Perin, P, Giunti, S, Grassi, G, Pagano, Gf, Porta, M, Sivieri, R, Vitelli, F, Veglio, M, Papazoglou, N, Manes, G

الوصف: CONTEXT AND OBJECTIVE: High-mobility group box-1 (HMGB1) is a pro-inflammatory cytokine that may contribute to the pathogenesis of micro- and macrovascular complications commonly observed in diabetes. We investigated whether HMGB1 is associated with: i) markers of low-grade inflammation (LGI) and endothelial dysfunction (ED) and pulse pressure (PP, a marker of arterial stiffness); ii) prevalent nephropathy, retinopathy and cardiovascular disease (CVD) in type 1 diabetes; and iii) the potential mediating roles of LGI, ED and PP therein. DESIGN AND METHODS: This was a cross-sectional nested case-control study of 463 patients (226 women; mean age 40±10 years) with type 1 diabetes from the EURODIAB Prospective Complications Study. We used linear and binary or multinomial logistic regression analyses adjusted for traditional risk factors. RESULTS: Serum Ln-HMGB1 levels were positively associated with LGI and ED (standardised β=0.07 (95% confidence interval (CI): 0.02-0.12) and β=0.08 (95% CI: 0.02-0.14) respectively), but not with PP. Higher Ln-HMGB1 (per unit) was associated with greater odds of micro- and macroalbuminuria: odds ratio (OR)=1.24 (95% CI: 0.90-1.71) and OR=1.61 (95% CI: 1.15-2.25) respectively, P for trend=0.004. Further adjustments for LGI or ED did not attenuate these associations. No such associations were found between Ln-HMGB1 and estimated glomerular filtration rate (eGFR), retinopathy or CVD, however. CONCLUSIONS: In type 1 diabetes, higher serum HMGB1 levels are associated with greater prevalence and severity of albuminuria, though not with eGFR, retinopathy and CVD. Prospective studies are needed to clarify the causal role of HMGB1, if any, in the pathogenesis of vascular complications in type 1 diabetes.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/22127490; info:eu-repo/semantics/altIdentifier/wos/WOS:000300295000023; volume:166; issue:2; firstpage:325; lastpage:332; numberofpages:8; journal:EUROPEAN JOURNAL OF ENDOCRINOLOGY; http://hdl.handle.net/11584/58104Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84856078195

الإتاحة: https://doi.org/10.1530/EJE-11-0662Test
http://hdl.handle.net/11584/58104Test

المؤلفون: Chaturvedi, Nish, Bandinelli, Simona, Mangili, Ruggero, Penno, Guiseppe, Rottiers, Raoul E., Fuller, John H., Karamanos, B., Kofinis, A., Petrou, K., Giorgino, R., Giorgino, F., Picca, G., Angarano, A., De Pergola, G., Ionescu-Tirgoviste, C., Coszma, A., Songini, M., Casu, A., Pedron, M., Fossarello, M., Ferriss, J. B., Grealy, G., Keefe, D. O., White, A., Cleary, P. E., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Kyostio-Renvall, T., Idzior-Walus, B., Sieradzki, J., Cyganek, K., Lemkes, H. H. P. J., Roest, C., Nunes-Correa, J., Rogado, M. C., Gardete-Correia, L., Cardoso, M. C., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Lattanzio, Rosangela, Galardi, G., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, D., Verier-Mine, O., Fuller, J. H., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D’ Alessandro, V., Cagini, C., Navalesi, R., Penno, G., Bandinelli, S., Miccoli, R., Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, A., Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Porta, M., Perin, P. Cavallo, Borra, M., Giunti, S., Papazoglou, N., Manes, Gianfranco, Muggeo, M., Iagulli, M., Irsigler, K., Abrahamian, H., Walford, S., Wardle, E. V., Sinclair, J., Hughes, S., Roglic, G., Metelko, Z., Resman, Z., Sjolie, A. -. K., Chaturvedi, N., Ferriss, B., Webb, D., Viberti, G. -. C., Swaminathan, R., Lumb, P., Collins, A., Sankaralingham, S., Aldington, S., Mortemore, T., Lipinski, H.

المصدر: Kidney International. 60:219-227

مصطلحات موضوعية: Albuminuria, Blood sugar control, Cardiovascular disease, Insulin resistance, Renal disease, Adolescent, Adult, Blood Glucose, Body Constitution, Cohort Studies, Diabetes Mellitus, Type 1, Differential Threshold, Disease Progression, Europe, Female, Follow-Up Studies, Humans, Incidence, Insulin Resistance, Male, Middle Aged, Prospective Studies, Reference Values, Risk Factors, Triglycerides, Nephrology, endocrine system diseases, urologic and male genital diseases, Gastroenterology, Waist–hip ratio, Proteinuria, Settore MED/30 - MALATTIE APPARATO VISIVO, female genital diseases and pregnancy complications, medicine.symptom, Type 1, medicine.medical_specialty, Internal medicine, Diabetes mellitus, Diabetes Mellitus, medicine, Risk factor, Glycemic, Type 1 diabetes, business.industry, nutritional and metabolic diseases, medicine.disease, Endocrinology, Microalbuminuria, business

الوصف: Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold.BackgroundThe occurrence of microalbuminuria in type 1 diabetes is strongly predictive of renal and cardiovascular disease and is still likely to occur despite improvements in glycemic control. A better understanding of microalbuminuria is required to inform new interventions. We determined the incidence and risk factors for microalbuminuria [albumin excretion rate (AER) 20 to 200 μg/min] in the EURODIAB Prospective Complications Study.MethodsThis is a seven-year follow-up (between 1988 and 1991) of 1134 normoalbuminuric men and women (aged 15 to 60) with type 1 diabetes from 31 European centers. Risk factors and AER were measured centrally.ResultsThe incidence of microalbuminuria was 12.6% over 7.3 years. Independent baseline risk factors were HbA1c (7.1 vs. 6.2%, P = 0.0001) and AER (9.6 vs. 7.8 μg/min, P = 0.0001) and, independent of these, fasting triglyceride (0.99 vs. 0.88 mmol/L, P = 0.01), low-density lipoprotein cholesterol (3.5 vs. 3.2 mmol/L, P = 0.02), body mass index (24.0 vs. 23.4 kg/m2, P = 0.01), and waist to hip ratio (WHR; 0.85 vs. 0.83, P = 0.009). Triglyceride and WHR risk factors were nearly as strong as AER in predicting microalbuminuria (standardized regression effects of 1.3 for triglyceride and WHR and 1.5 for AER). Blood pressure at follow-up, but not at baseline, was also raised in those who progressed. There was no evidence of a threshold of HbA1c on microalbuminuria risk.ConclusionsThe incidence of microalbuminuria in patients with type 1 diabetes remains high, and there is no apparent glycemic threshold for it. Markers of insulin resistance, such as triglyceride and WHR, are strong risk factors. Systemic blood pressure is not raised prior to the onset of microalbuminuria.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2556bd8b447ca8ee9908bb7998f9d141Test
https://doi.org/10.1046/j.1523-1755.2001.00789.xTest

المؤلفون: Delcourt, C., Papoz, L., Villatte‐Cathelineau, B., Cathelineau, G., Vauzelle‐Kervroedan, F.

المصدر: Acta Ophthalmologica Scandinavica ; volume 73, issue 4, page 293-298 ; ISSN 1395-3907 1600-0420

الوصف: The prevalence and causes of visual impairment have been estimated in a sample of 423 Type 2 diabetic outpatients, aged 35 to 74 years, recruited in 8 centres from all parts of France. The presence of retinopathy was assessed by fluorescein angiography with centralized interpretation. The presence of cataract and glaucoma was also recorded. Prevalence of blindness was 1.2%. Moderate visual impairment affected 7% of the patients. The major cause of blindness was cataract, explaining 38% of the cases of blindness. Retinopathy was associated to blindness in 2 cases out of 26. More than half of the patients with proliferative retinopathy and the third of those who had macular edema had been treated by photocoagulation. According to the present patient material, retinopathy is a minor cause of visual impairment in Type 2 diabetic patients, cataract remaining the major cause. This reflects the introduction of photocoagulation into ophthalmologic pratice.

الإتاحة: https://doi.org/10.1111/j.1600-0420.1995.tb00029.xTest

المؤلفون: Delcourt, C., Villatte-Cathelineau, B., Vauzelle-Kervroedan, F., Papoz, L.

المصدر: Journal of Clinical Epidemiology; 1996, Vol. 49 Issue: 6 p679-685, 7p

المؤلفون: Sjølie, Anne Katrin, Stephenson, Judith, Aldington, Steve, Kohner, Eva, Janka, Hans, Stevens, Lynda, Fuller, John, Karamanos, B., Tountas, C., Kofinis, A., Petrou, K., Katsilambros, N., Cignarelli, M., Giorgino, R., Cignarelli, M., De Geco, M.L., Ramunni, I., Ionescu-Tirgoviste, C., Iosif, C.M., Pitei, C., Buligescu, S., Tamas, G., Kerenyi, Z., Ahmed, A.M., Toth, J., Kempler, P., Muntoni, S., Songini, M., Stabilini, M., Fossarello, M., Pintus, S., Ferriss, B., Cronin, C.C., Toeller, M., Klischan, A., Forst, T., Gries, F.A., Rottiers, R., Priem, H., Ebeling, P., Sinisalo, M., Koivisto, V.A., Idzior-Walus, B., Solnica, B., Szopinska-Ciba, L., Solnica, K., Krans, H.M.J., Lemkes, H.H.P.J., Jansen, J.J., Nunes-Cornea, J., Boavida, J., Michel, G., Wirion, R., Boulton, A.J.M., Ashe, H., Fernando, D.J.S., Pozza, G., Slaviero, G., Comi, G., Fattor, B., Bandello, F., Mehnert, H., Nuber, A., Janka, H., Ben Soussan, D., Fallas, M.C., Fallas, P., Jepson, E., McHardy-Young, S., Fuller, J.H., Betteridge, D.J., Milne, M., Crepaldi, G., Nosadini, R., Cathelineau, G., Villatte Cathelineau, B., Jellal, M., Grodner, N., Gervais Feiss, P., Santeusanio, F., Rosi, G., Ventura, M.R.M., Cagini, C., Marino, C., Navalesi, R., Penno, G., Miccoli, R., Nannipieri, M., Manfredi, S., Ghirlanda, G., Cotroneo, P., Manto, A., Teodonio, C., Minnella, A., Ward, J.D., Tesfaye, S., Mody, C., Rudd, C., Molinatti, G.M., Vitelli, F., Porta, M., Pagano, G.F., Cavallo Perin, P., Estivi, P., Sivieri, R., Carta, Q., Petraroli, G., Papazoglou, N., Manes, G., Triantaphyllou, G., Ioannides, A., Muggeo, M., Cacciatori, V., Bellavere, F., Galante, P., Gemma, M.L., Irsigler, K., Abrahamian, H., Gurdet, C., Hornlein, B., Willinger, C., Walford, S., Wardle, E.V., Roglic, G., Resman, Z., Metelko, Z., Skrabalo, Z.

المصدر: Ophthalmology; February 1997, Vol. 104 Issue: 2 p252-260, 9p

مستخلص: Purpose:To assess the frequency of retinopathy and vision loss in patients with insulin-dependent diabetes mellitus and their relations to potentially modifiable risk factors.

المؤلفون: Peeters, Stijn A., Engelen, Lian, Buijs, Jacqueline, Chaturvedi, Nish, Fuller, John H., Schalkwijk, Casper G., Stehouwer, Coen D, Karamanos, B., Kofinis, A., Petrou, K., Giorgino, F., Picca, G., Angarano, A., Null, de P. e. r. g. o. l. a. G., Laviola, L., Giorgino, R., Ionescu Tirgoviste, C., Coszma, A., Guja, C., Songini, M., Casu, A., Pedron, M., Pintus, S., Fossarello, M., Ferriss, J. B., Grealy, G., O'Keefe, D., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Koivisto, V. A., Idzior Walus, B., Sieradzki, J., Cyganek, K., Solnica, B., Lemkes, H. H. P. J., Lemkes Stuffken, J. C., Nunes Correa, J., Rogado, M. C., Gardete Correia, L., Cardoso, M. C., Silva, A., Boavida, J., Machado Sa Marques, M., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, M., Verier Mine, O., Fallas, P., Fallas, M. C., Fuller, J. H., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D'Alessandro, V., Cagini, C., Bottini, P., Reboldi, G. P., Navalesi, R., Penno, Giuseppe, Bandinelli, S., Miccoli, Roberto, Nannipieri, Monica, Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, A., Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Borra, M., Cavallo Perin, P., Giunti, S., Grassi, G., Pagano, G. F., Porta, M., Sivieri, R., Vitelli, F., Veglio, M., Papazoglou, N., Manes, G., Muggeo, M., Iagulli, M., Cacciatori, V., Cattedra di Malattie del Metabolismo, V., Irsigler, K., Abrahamian, H., Walford, S., Sinclair, J., Hughes, S., Mclelland, V., Ward, J., Roglic, G., Metelko, Z., Pepeonik, Z. R.

المساهمون: Clinicum, Department of Medicine, Interne Geneeskunde, MUMC+: MA Interne Geneeskunde (3), RS: CARIM - R3 - Vascular biology

المصدر: Cardiovascular Diabetology
Cardiovascular Diabetology, 14:31. BioMed Central Ltd

مصطلحات موضوعية: Male, Endocrinology, Diabetes and Metabolism, Matrix metalloproteinase, Gastroenterology, Cohort Studies, Endocrinology, Prospective Studies, Endothelial dysfunction, Original Investigation, Settore MED/30 - MALATTIE APPARATO VISIVO, Middle Aged, Cardiovascular disease, 3. Good health, Europe, Diabetes and Metabolism, Albuminuria, Retinopathy, Tissue inhibitor of metalloproteinase, Type 1 diabetes, Adult, Biomarkers, Cross-Sectional Studies, Diabetes Complications, Diabetes Mellitus, Type 1, Female, Humans, Matrix Metalloproteinase 10, Matrix Metalloproteinase 2, Matrix Metalloproteinase 3, Tissue Inhibitor of Metalloproteinase-1, Vascular Diseases, Cardiology and Cardiovascular Medicine, medicine.symptom, Type 1, medicine.medical_specialty, education, Inflammation, Diabetes mellitus, Internal medicine, medicine, Diabetes Mellitus, business.industry, Settore MED/09 - MEDICINA INTERNA, medicine.disease, 3121 General medicine, internal medicine and other clinical medicine, business

الوصف: Background Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1 diabetes. We investigated associations between plasma MMP-1, −2, −3, −9, −10 and TIMP-1, and cardiovascular disease (CVD) or microvascular complications in type 1 diabetic patients. We also evaluated to which extent these associations could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED). Methods 493 type 1 diabetes patients (39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective Complications Study were included. Linear regression analysis was applied to investigate differences in plasma levels of MMP-1, −2, −3, −9, −10, and TIMP-1 between patients with and without CVD, albuminuria or retinopathy. All analyses were adjusted for age, sex, duration of diabetes, Hba1c and additionally for other cardiovascular risk factors including LGI and ED. Results Patients with CVD (n = 118) showed significantly higher levels of TIMP-1 [β = 0.32 SD (95%CI: 0.12; 0.52)], but not of MMPs, than patients without CVD (n = 375). Higher plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1 were associated with higher levels of albuminuria (p-trends were 0.028, 0.004, 0.005 and 0.001, respectively). Severity of retinopathy was significantly associated with higher levels of MMP-2 (p-trend = 0.017). These associations remained significant after further adjustment for markers of LGI and ED. Conclusions These data support the hypothesis that impaired regulation of matrix remodeling by actions of MMP-2, -3 and-10 and TIMP-1 contributes to the pathogenesis of vascular complications in type 1 diabetes. Electronic supplementary material The online version of this article (doi:10.1186/s12933-015-0195-2) contains supplementary material, which is available to authorized users.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78226d7d86ee0e00241b8f5e4f5f1456Test

المؤلفون: Manto A., Minnella A.

المساهمون: Peeters, S. A., Engelen, L., Buijs, J., Chaturvedi, N., Fuller, J. H., Schalkwijk, C. G., Stehouwer, C. D., Karamanos, B., Kofinis, A., Petrou, K., Giorgino, F., Picca, G., Angarano, A., De, Pergola. G., Laviola, L., Giorgino, R., Ionescu-Tirgoviste, C., Coszma, A., Guja, C., Songini, M., Casu, A., Pedron, M., Pintus, S., Fossarello, M., Ferriss, J. B., Grealy, G., O'Keefe, D., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Koivisto, V. A., Idzior-Walus, B., Sieradzki, J., Cyganek, K., Solnica, B., Lemkes, H. H. P. J., Lemkes-Stuffken, J. C., Nunes-Correa, J., Rogado, M. C., Gardete-Correia, L., Cardoso, M. C., Silva, A., Boavida, J., Machado Sa Marques, M., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, M., Verier-Mine, O., Fallas, P., Fallas, M. C., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D'Alessandro, V., Cagini, C., Bottini, P., Reboldi, G. P., Navalesi, R., Penno, G., Bandinelli, S., Miccoli, R., Nannipieri, M., Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, Andrea, Minnella, Angelo Maria, Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Borra, M., Cavallo Perin, P., Giunti, S., Grassi, G., Pagano, G. F., Porta, M., Sivieri, R., Vitelli, F., Veglio, M., Papazoglou, N., Manes, G.

مصطلحات موضوعية: Albuminuria, Cardiovascular disease, Matrix metalloproteinase, Retinopathy, Tissue inhibitor of metalloproteinase, Type 1 diabete, Adult, Biomarker, Cohort Studie, Cross-Sectional Studie, Diabetes Complication, Diabetes Mellitus, Type 1, Europe, Female, Human, Male, Matrix Metalloproteinase 10, Matrix Metalloproteinase 2, Matrix Metalloproteinase 3, Middle Aged, Prospective Studie, Tissue Inhibitor of Metalloproteinase-1, Vascular Diseases, Settore MED/09 - MEDICINA INTERNA, Settore MED/30 - MALATTIE APPARATO VISIVO

الوصف: Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1 diabetes. We investigated associations between plasma MMP-1, -2, -3, -9, -10 and TIMP-1, and cardiovascular disease (CVD) or microvascular complications in type 1 diabetic patients. We also evaluated to which extent these associations could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED). Methods: 493 type 1 diabetes patients (39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective Complications Study were included. Linear regression analysis was applied to investigate differences in plasma levels of MMP-1, -2, -3, -9, -10, and TIMP-1 between patients with and without CVD, albuminuria or retinopathy. All analyses were adjusted for age, sex, duration of diabetes, Hba1c and additionally for other cardiovascular risk factors including LGI and ED. Results: Patients with CVD (n = 118) showed significantly higher levels of TIMP-1 [β = 0.32 SD (95%CI: 0.12; 0.52)], but not of MMPs, than patients without CVD (n = 375). Higher plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1 were associated with higher levels of albuminuria (p-trends were 0.028, 0.004, 0.005 and 0.001, respectively). Severity of retinopathy was significantly associated with higher levels of MMP-2 (p-trend = 0.017). These associations remained significant after further adjustment for markers of LGI and ED. Conclusions: These data support the hypothesis that impaired regulation of matrix remodeling by actions of MMP-2, -3 and-10 and TIMP-1 contributes to the pathogenesis of vascular complications in type 1 diabetes.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/25848912; info:eu-repo/semantics/altIdentifier/wos/WOS:000350726000001; volume:14; issue:1; firstpage:N/A; lastpage:N/A; issueyear:2015; journal:CARDIOVASCULAR DIABETOLOGY; https://hdl.handle.net/10807/233627Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84925234995

الإتاحة: https://doi.org/10.1186/s12933-015-0195-2Test
https://hdl.handle.net/10807/233627Test

المؤلفون: Minnella A.

المساهمون: Chaturvedi, N., Bandinelli, S., Mangili, R., Penno, G., Rottiers, R. E., Fuller, J. H., Karamanos, B., Kofinis, A., Petrou, K., Giorgino, R., Giorgino, F., Picca, G., Angarano, A., De Pergola, G., Ionescu-Tirgoviste, C., Coszma, A., Songini, M., Casu, A., Pedron, M., Fossarello, M., Ferriss, J. B., Grealy, G., Keefe, D. O., White, A., Cleary, P. E., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Kyostio-Renvall, T., Idzior-Walus, B., Sieradzki, J., Cyganek, K., Lemkes, H. H. P. J., Roest, C., Nunes-Correa, J., Rogado, M. C., Gardete-Correia, L., Cardoso, M. C., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Asnaghi, V., Lattanzio, R., Galardi, G., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, D., Verier-Mine, O., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D' Alessandro, V., Cagini, C., Navalesi, R., Miccoli, R., Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, Angelo Maria, Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Porta, M., Perin, P. C., Borra, M., Giunti, S., Papazoglou, N., Manes, G., Muggeo, M., Iagulli, M., Irsigler, K., Abrahamian, H., Walford, S., Wardle, E. V., Sinclair, J., Hughes, S., Roglic, G., Metelko, Z., Resman, Z., Sjolie, A. -K.

مصطلحات موضوعية: Albuminuria, Blood sugar control, Cardiovascular disease, Insulin resistance, Renal disease, Settore MED/30 - MALATTIE APPARATO VISIVO

الوصف: Background. The occurrence of microalbuminuria in type 1 diabetes is strongly predictive of renal and cardiovascular disease and is still likely to occur despite improvements in glycemic control. A better understanding of microalbuminuria is required to inform new interventions. We determined the incidence and risk factors for microalbuminuria [albumin excretion rate (AER) 20 to 200 μg/min] in the EURODIAB Prospective Complications Study. Methods. This is a seven-year follow-up (between 1988 and 1991) of 1134 normoalbuminuric men and women (aged 15 to 60) with type 1 diabetes from 31 European centers. Risk factors and AER were measured centrally. Results. The incidence of microalbuminuria was 12.6% over 7.3 years. Independent baseline risk factors were HbA1c (7.1 vs. 6.2%, P = 0.0001) and AER (9.6 vs. 7.8 μ/min, P = 0.0001) and, independent of these, fasting triglyceride (0.99 vs. 0.88 mmol/L, P = 0.01), low-density lipoprotein cholesterol (3.5 vs. 3.2 mmol/L, P = 0.02), body mass index (24.0 vs. 23.4 kg/m2, P = 0.01), and waist to hip ratio (WHR; 0.85 vs. 0.83, P = 0.009). Triglyceride and WHR risk factors were nearly as strong as AER in predicting microalbuminuria (standardized regression effects of 1.3 for triglyceride and WHR and 1.5 for AER). Blood pressure at follow-up, but not at baseline, was also raised in those who progressed. There was no evidence of a threshold of HbA1c on microalbuminuria risk. Conclusions. The incidence of microalbuminuria in patients with type 1 diabetes remains high, and there is no apparent glycemic threshold for it. Markers of insulin resistance, such as triglyceride and WHR, are strong risk factors. Systemic blood pressure is not raised prior to the onset of microalbuminuria.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/11422754; info:eu-repo/semantics/altIdentifier/wos/WOS:000169496000024; volume:60; issue:1; firstpage:219; lastpage:227; numberofpages:9; issueyear:2001; journal:KIDNEY INTERNATIONAL; https://hdl.handle.net/10807/233693Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-0034951267

الإتاحة: https://doi.org/10.1046/j.1523-1755.2001.00789.xTest
https://hdl.handle.net/10807/233693Test